In November 2023, the U.S. Food and Drug Administration licensed a vaccine for chikungunya virus for adults aged 18 years and older. An Advisory Committee on Immunization Practices (ACIP) Work Group is currently reviewing the data on this chikungunya vaccine and considering use of the vaccine in people in the United States at risk of chikungunya, including those who travel abroad, laboratory workers working with chikungunya virus, and residents of U.S. states and territories with, or at risk of, transmission. This Work Group is developing vaccine recommendations for ACIP to consider. Final recommendations will be posted on CDC’s ACIP vaccine website when available, please check back for updates.
Chikungunya virus is spread to people by the bite of an infected mosquito. The most common symptoms of infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Americas, Asia, Europe, and the Caribbean, Indian and Pacific Oceans. There is a risk the virus will be spread to unaffected areas by infected travelers. There is currently no medicine to treat chikungunya virus infection. Travelers can protect themselves by preventing mosquito bites. When traveling to countries with chikungunya virus, use insect repellent; wear long-sleeved shirts and pants; and stay in places with air conditioning or that use window and door screens.